{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:22:05Z","timestamp":1793305325165,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.xphs.2023.06.013","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T11:10:21Z","timestamp":1687605021000},"page":"3075-3087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-0449","authenticated-orcid":false,"given":"Diaa","family":"Shakleya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethel","family":"Asmelash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaadin","family":"Alayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-8642","authenticated-orcid":false,"given":"Nicolas","family":"Abrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-1088","authenticated-orcid":false,"given":"Adil","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-3030","authenticated-orcid":false,"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-717X","authenticated-orcid":false,"given":"Jingyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Andres","family":"Marzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Shaklah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahd M.","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaniya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Faustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Raw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilayat A.","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-7904","authenticated-orcid":false,"given":"David","family":"Keire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2023.06.013_bib0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/dtb.2021.000041","article-title":"Cancer risk from nitrosamine-contaminated valsartan","volume":"59","year":"2021","journal-title":"Drug Ther Bull"},{"issue":"21","key":"10.1016\/j.xphs.2023.06.013_bib0002","first-page":"357","article-title":"N-nitrosodimethylamine-contaminated valsartan and the risk of cancer\u2014a longitudinal cohort study based on German health insurance data","volume":"118","author":"Gomm","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.xphs.2023.06.013_bib0003","doi-asserted-by":"crossref","first-page":"k3851","DOI":"10.1136\/bmj.k3851","article-title":"Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: danish nationwide cohort study","volume":"362","author":"Potteg\u00e5rd","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.xphs.2023.06.013_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2019.04.035","article-title":"The contamination of valsartan and other sartans, Part 2: untargeted screening reveals contamination with amides additionally to known nitrosamine impurities","volume":"172","author":"Scherf-Clavel","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2023.06.013_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yrtph.2019.01.007","article-title":"Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products","volume":"103","author":"Snodin","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2023.06.013_bib0006","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","article-title":"Nitrosamine contamination in pharmaceuticals: threat, impact, and control","volume":"110","author":"Tuesuwan","year":"2021","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2023.06.013_bib0007","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.xphs.2022.12.005","article-title":"Rapid quantitation of four nitrosamine impurities in angiotensin receptor blocker drug substances","volume":"112","author":"Zhang","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.06.013_bib0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/14740338.2021.1983310","article-title":"Reply to the article 'Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products","volume":"21","author":"Mintert","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.xphs.2023.06.013_bib0009","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/14740338.2021.1917547","article-title":"Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products","volume":"20","author":"Nasr","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"22","key":"10.1016\/j.xphs.2023.06.013_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225304","article-title":"N-nitrosodimethylamine contamination in the metformin finished products","volume":"25","author":"Zmyslowski","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.xphs.2023.06.013_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14740338.2021.1983312","article-title":"Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products","volume":"21","author":"Nasr","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.xphs.2023.06.013_bib0012","article-title":"In-use stability assessment of FDA approved metformin immediate release and extended release products for N-nitrosodimethylamine and dissolution quality attributes","volume":"25","author":"Dharani","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2023.06.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113877","article-title":"Insight into the formation of N-nitrosodimethylamine in metformin products","volume":"195","author":"Jire\u0161","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2023.06.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114872","article-title":"N-Nitrosation in the absence of nitrosating agents in pharmaceuticals?","volume":"218","author":"Jire\u0161","year":"2022","journal-title":"J Pharm Biomed Anal"},{"issue":"20","key":"10.1016\/j.xphs.2023.06.013_bib0015","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.2021.16261","article-title":"Risk of N-nitrosodimethylamine (NMDA) formation With ranitidine","volume":"326","author":"Strauss","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.xphs.2023.06.013_bib0016","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jama.2021.9199","article-title":"Effect of oral ranitidine on urinary excretion of N-nitrosodimethylamine (NDMA): a randomized clinical trial","volume":"326","author":"Florian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.xphs.2023.06.013_bib0017","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1039\/D2AY01821G","article-title":"A highly sensitive LC-MS\/MS method for the determination and quantification of a recently identified N-nitrosamine impurity in the sitagliptin phosphate monohydrate active pharmaceutical ingredient","volume":"15","author":"Wang","year":"2023","journal-title":"Anal Methods"},{"key":"10.1016\/j.xphs.2023.06.013_bib0018","series-title":"FDA updates regulatory flexibility concerning N-nitroso-varenicline intake limits","year":"2022"},{"key":"10.1016\/j.xphs.2023.06.013_bib0019","series-title":"FDA updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products","year":"2021"},{"key":"10.1016\/j.xphs.2023.06.013_bib0020","series-title":"FDA updates and press announcements on angiotensin II receptor blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan)","year":"2019"},{"key":"10.1016\/j.xphs.2023.06.013_bib0021","series-title":"Control of nitrosamine impurities in human drugs: Guidance for industry","year":"2021"},{"key":"10.1016\/j.xphs.2023.06.013_bib0022","unstructured":"USFDA. Information about nitrosamine impurities in medications. USFDA;2021."},{"issue":"4","key":"10.1016\/j.xphs.2023.06.013_bib0023","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000225444","article-title":"Carcinogenicity of N-nitroso compounds. Species and route differences in regard to organotropism","volume":"37","author":"Schm\u00e4hl","year":"1980","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.xphs.2023.06.013_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-022-00702-4","article-title":"International regulatory collaboration on the analysis of nitrosamines in metformin-containing medicines","volume":"24","author":"Keire","year":"2022","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2023.06.013_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10337-021-04115-x","article-title":"A critical N\u2011nitrosamine impurity of anticoagulant drug, rivaroxaban: synthesis, characterization, development of LC\u2013MS\/MS method for nanogram level quantification","volume":"85","author":"Baksam","year":"2022","journal-title":"Chromatographia"},{"key":"10.1016\/j.xphs.2023.06.013_bib0026","series-title":"FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity","year":"2018"},{"key":"10.1016\/j.xphs.2023.06.013_bib0027","series-title":"Questions and Answers: NDMA impurities in metformin products","year":"2020"},{"key":"10.1016\/j.xphs.2023.06.013_bib0028","series-title":"FDA updates and press announcements on NDMA in metformin","year":"2021"},{"key":"10.1016\/j.xphs.2023.06.013_bib0029","series-title":"Information note nitrosamine impurities","year":"2019"},{"key":"10.1016\/j.xphs.2023.06.013_bib0030","series-title":"Nitrosamine impurities","year":"2021"},{"issue":"5","key":"10.1016\/j.xphs.2023.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","article-title":"Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals","volume":"112","author":"Horne","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.06.013_bib0032","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","article-title":"An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals","volume":"31","author":"Wichitnithad","year":"2023","journal-title":"Saudi Pharma J"},{"key":"10.1016\/j.xphs.2023.06.013_bib0033","first-page":"297","article-title":"General considerations N\u2013nitrosatable drugs","volume":"24","year":"1980","journal-title":"IARC Monogr Eval Carcinog Risk Chem Hum"},{"key":"10.1016\/j.xphs.2023.06.013_bib0034","first-page":"1","article-title":"IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds","volume":"17","year":"1978","journal-title":"IARC Monogr Eval Carcinog Risk Chem Man"},{"key":"10.1016\/j.xphs.2023.06.013_bib0035","series-title":"Determination of genotoxic nitrosamine impurity in bumetanide API and tablets using the Agilent 6470 Triple Quadrupole LC\/MS","year":"2020"},{"key":"10.1016\/j.xphs.2023.06.013_bib0036","series-title":"Committee for medicinal products for human use (CHMP)","year":"2022"},{"issue":"12","key":"10.1016\/j.xphs.2023.06.013_bib0037","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","article-title":"Inhibition of N-nitrosamine formation in drug products: a model study","volume":"110","author":"Nanda","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.06.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121740","article-title":"Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite","volume":"620","author":"Schlingemann","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2023.06.013_bib0039","article-title":"N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: effects of metformin and hypromellose used in drug product formulation","volume":"222","author":"Hao","year":"2022","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"10.1016\/j.xphs.2023.06.013_bib0040","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/pr10112428","article-title":"Assessment of a diverse array of nitrite scavengers in solution and solid state: a study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives","volume":"10","author":"Hom\u0161ak","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.xphs.2023.06.013_bib0041","article-title":"Inhibitory effects of vitamin C and E on in-vitro formation of N-nitrosamine under physiological conditions","author":"Lathia","year":"1988","journal-title":"Progress in Diet and Nutrition"},{"issue":"3","key":"10.1016\/j.xphs.2023.06.013_bib0042","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/carcin\/5.3.309","article-title":"Caffeic and ferulic acid as blockers of nitrosamine formation","volume":"5","author":"Kuenzig","year":"1984","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xphs.2023.06.013_bib0043","series-title":"Ascorbic acid inhibition of N-nitroso compound formation in chemical, food, and biological systems","first-page":"101","author":"Mirvish","year":"1981"},{"issue":"9","key":"10.1016\/j.xphs.2023.06.013_bib0044","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"2","key":"10.1016\/j.xphs.2023.06.013_bib0045","article-title":"Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry","volume":"223","author":"Gimenez-Campillo","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.xphs.2023.06.013_bib0046","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1208\/s12248-020-00473-w","article-title":"A Cautionary tale: quantitative LC-HRMS analytical procedures for the analysis of n-nitrosodimethylamine in metformin","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2023.06.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113460","article-title":"Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry","volume":"189","author":"Lim","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2023.06.013_bib0048","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.xphs.2023.06.013_bib0049","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1208\/s12248-021-00669-8","article-title":"A full evaporation static headspace gas chromatography method with nitrogen phosphorous detection for ultrasensitive analysis of semi-volatile nitrosamines in pharmaceutical products","volume":"24","author":"Zheng","year":"2022","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2023.06.013_bib0050","doi-asserted-by":"crossref","first-page":"e06179","DOI":"10.1016\/j.heliyon.2021.e06179","article-title":"Determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation","volume":"7","author":"Hu","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.xphs.2023.06.013_bib0051","series-title":"Analytical procedures and methods validation for drugs and biologics: guidance for industry","year":"2020"},{"key":"10.1016\/j.xphs.2023.06.013_bib0052","series-title":"Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry","year":"2021"},{"key":"10.1016\/j.xphs.2023.06.013_bib0053","year":"2021","journal-title":"Validation of compendial procedures."},{"key":"10.1016\/j.xphs.2023.06.013_bib0054","series-title":"CHROMATOGRAPHY","year":"2022"},{"key":"10.1016\/j.xphs.2023.06.013_bib0055","unstructured":"USP. Monograph U: Bumetanide USP 42-NF37."},{"issue":"5","key":"10.1016\/j.xphs.2023.06.013_bib0056","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2022","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2023.06.013_bib0057","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/j.2050-0416.1986.tb04373.x","article-title":"The chemistry of nitrosamine formation: relevance to malting and brewing","volume":"92","author":"Wainright","year":"1986","journal-title":"J Ins Brewing"},{"issue":"9","key":"10.1016\/j.xphs.2023.06.013_bib0058","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1021\/jf000147+","article-title":"Potential nitrite scavengers as inhibitors of the formation of N-nitrosamines in solution and tobacco matrix systems","volume":"48","author":"Rundl\u00f6f","year":"2000","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.xphs.2023.06.013_bib0059","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.foodchem.2014.11.101","article-title":"Formation and mitigation of N-nitrosamines in nitrite preserved cooked sausages","volume":"174","author":"Herrmann","year":"2015","journal-title":"Food Chem"},{"issue":"4","key":"10.1016\/j.xphs.2023.06.013_bib0060","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.xphs.2023.06.013_bib0061","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A nitrite excipient database: a useful tool to support N-nitrosamine risk assessments for drug products","volume":"112","author":"Boetzel","year":"2022","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:42:52Z","timestamp":1758361372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923002447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0022354923002447"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.06.013","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}